Cell Genesys GVAX Prostate Cancer Vaccine Will Begin Phase III Under Special Protocol Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trial program will attempt to demonstrate superiority over taxane chemotherapy in treating hormone-refractory metastatic prostate cancer patients. Cell Genesys hopes to highlight tolerability, dosing convenience of vaccine if approved.
You may also be interested in...
Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.
Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009
Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.
Medarex To Start Pivotal Trial Of MDX-010/Cancer Vaccine Combo For Melanoma
The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.